|
|
|
11-50 employees
View all
|
|
Biotechnology
|
|
953 Indiana St, San Francisco, California 94107, US
|
|
Senescent cells, which are characterized by irreversible damage and an inflammatory secretome, are considered a key driving force behind many age-related diseases. Due to a failure in immune surveillance, senescent cells accumulate and impact their local environment by inducing inflammation and promoting extracellular matrix remodeling, thus resulting in a myriad of metabolic and fibrotic consequences. Therefore, enabling the removal of senescent cells dramatically ameliorates disease pathologies in many age-related diseases, leading to overall improvements in health-span.
At Deciduous Therapeutics, we have discovered novel molecules that can activate a critical endogenous immune surveillance mechanism to selectively remove senescent cells and thereby treat several classes of age-related diseases.
|
Deciduous Therapeutics Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used Deciduous Therapeutics email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact Deciduous Therapeutics customer service number in your country click here to find.
Robin Mansukhani is the CEO of Deciduous Therapeutics. To contact Robin Mansukhani email at [email protected] or [email protected].
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.